Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
By S. Lonial, M. Dimopoulos, A. Palumbo, D. White, S. Grosicki, I. Špička, A. Walter‐Croneck, P. Moreau, M. Mateos, H. Magen and 18 more. New England Journal of Medicine, 2015
1,235 citations recorded by the source corpus.
Subfields: Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/fb9d8d9019089b66fbe8ecd85963014c537e649e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Connecting genetic risk to disease end points through the human blood plasma proteome (2016, neutral): “This hypothesis can be tested retrospectively in the phase-3 clinical trial cohort 47 .”
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. (2015, neutral): “Allergic rhinitis 12 (40) 0 10 (24) 0 22 (31) 0”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).(82) Elotuzumab is well tolerated, and was initially approved in 2015 by the FDA to be given in com-”
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016, neutral): “Data not available 86 (24) 84 (23) 170 (24)”
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Elotuzumab, a monoclonal antibody targeting the signaling lymphocytic activation molecule F7 (SLAMF7).(71) Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).”